Sandesh Mahatme - Jun 5, 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Director
Signature
/s/ Elizabeth Ryland Waldinger
Stock symbol
CRSP
Transactions as of
Jun 5, 2025
Transactions value $
$0
Form type
4
Date filed
6/6/2025, 05:30 PM
Previous filing
May 30, 2024
Next filing
Jul 10, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mahatme Sandesh Director C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON /s/ Elizabeth Ryland Waldinger 2025-06-06 0001511034

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Award $0 +13K $0.00 13K Jun 5, 2025 Common Shares 13K $38.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders.